HUMULIN N (insulin human) by Eli Lilly and Company. Approved for insulin [epc]. First approved in 1982.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
HUMULIN N is a human insulin injection approved in 1982 for the treatment of diabetes mellitus. It is an intermediate-acting insulin that helps regulate blood glucose levels in patients who cannot produce adequate insulin naturally. The drug works by mimicking endogenous insulin to facilitate glucose uptake and metabolism.
Product is in mature phase with significant Part D claims (338,740 annually) but faces LOE pressure; commercial teams are likely focused on brand defense and channel management rather than growth initiatives.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.
Worked on HUMULIN N at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
HUMULIN N offers limited career advancement opportunities due to its mature, LOE-approaching lifecycle with no active development pipeline. Roles on this product focus on defensive commercial execution, cost management, and operational efficiency rather than innovation or market expansion.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo